Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA410965
Max Phase: Preclinical
Molecular Formula: C83H91N11O19
Molecular Weight: 1546.70
Molecule Type: Protein
Associated Items:
ID: ALA410965
Max Phase: Preclinical
Molecular Formula: C83H91N11O19
Molecular Weight: 1546.70
Molecule Type: Protein
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)NC(=O)[C@H](CCCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)O
Standard InChI: InChI=1S/C83H91N11O19/c1-3-5-20-62(88-78(107)64(41-51-29-37-58(96)38-30-51)91-81(110)67(44-71(98)99)87-70(97)47-86-75(104)60(84)39-48-27-35-57(95)36-28-48)76(105)90-65(40-49-23-31-54(32-24-49)73(102)52-15-9-7-10-16-52)79(108)92-66(43-56-46-85-61-22-14-13-19-59(56)61)80(109)89-63(21-6-4-2)77(106)93-68(45-72(100)101)82(111)94-69(83(112)113)42-50-25-33-55(34-26-50)74(103)53-17-11-8-12-18-53/h7-19,22-38,46,60,62-69,85,95-96H,3-6,20-21,39-45,47,84H2,1-2H3,(H,86,104)(H,87,97)(H,88,107)(H,89,109)(H,90,105)(H,91,110)(H,92,108)(H,93,106)(H,94,111)(H,98,99)(H,100,101)(H,112,113)/t60-,62+,63+,64+,65+,66+,67+,68+,69+/m1/s1
Standard InChI Key: RGBNLPYNNSAMFQ-GCQITNQYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1546.70 | Molecular Weight (Monoisotopic): 1545.6493 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ.. (1999) A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely., 42 (12): [PMID:10377216] [10.1021/jm980732q] |
Source(1):